HUBBARD, Ohio, June 13, 2012 /PRNewswire/ -- NanoLogix (OTC
Markets:NNLX) announced today its R&D team in collaboration
with University of Texas Health Science Center -
Houston (UTHSC-Houston) researchers, are developing a
multi-well, microplate reader variant of the company's
BioNanoFilter (BNF) diagnostics for use in large volume
laboratory environments. Early analysis of the
multi-well plates shows exceptionally fast live-threat results
similar to the company's standard BNF technology. Starting
this week, the NanoLogix BNF and BioNanoPore (BNP) technology will
be on exhibit at booth #841 at the 112th General Meeting of
the American Society for Microbiology in San Francisco, June
16 – June 19.
(Photo:
http://photos.prnewswire.com/prnh/20120613/CL23734)
Research using NanoLogix technology from a recently completed
clinical study will also be presented at the ASM General Meeting on
June 17th. Dr. Jonathan Faro
of UTHSC-Houston will present the research, which focused on
detection, identification, and determination of antibiotic
sensitivity of Group B Streptococcus (GBS) during
pregnancy. Data showed NanoLogix diagnostics consistently
provided results in a 4 to 6 hour window, dramatically shorter than
standard culturing times of 48 to 72 hours. The data and the
associated clinical study narrative is currently being formatted
for submission for peer-review publication, as well as to the US
FDA for acceptance as a non-invasive diagnostic
technology.
"These are exciting times for NanoLogix," said CEO Bret Barnhizer. "Our technology has the
potential to dramatically affect the course of human health and
events over the past eight months have greatly
enhanced our position for
the future."
Rapid Live-Threat Tuberculosis Results
Recent R&D operations have also converged to dramatically
enrich NanoLogix' bacteria and protozoa detection technology
portfolio.
The detection for Tuberculosis (TB) utilizing NanoLogix' BNF and
BioNanoPore (BNP) technologies has recently been completed by a
major independent, third-party research laboratory.
Live-threat TB was detected with NanoLogix BNP technology in 4 to 5
days, as opposed to 21 to 84 days with standard culture. TB
was also detected and identified with the company's BNF technology
in less than two hours. Peer-reviewed publication and FDA
submittal are in process for results from both BNP and BNF
Tuberculosis research.
"We are thrilled to be dramatically cutting bacterial detection
times from days to hours for many pathogens," said Barnhizer.
"Specifically, we have reduced wait times for TB from weeks to
days, while protozoa detection times for Cryptosporidium,
which is responsible for over 50 percent of waterborne illnesses,
have been cut from weeks to hours. At the same time, we have
been able to accomplish these results with improved quality of
detection."
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology, microbial physiology,
molecular biology, pharmacology, pharmaco-kinetics, and antibiotic
sensitivity. For more information visit
www.nanologix.com.
Media Contact:
Lisa Ann Pinkerton
Technica Communications for NanoLogix
408-806-9626
lisaann@technicacommunications.com
Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
SOURCE NanoLogix, Inc.